La maladie de Parkinson au Canada (serveur d'exploration) - Exploration (Accueil)

Index « Keywords » - entrée « Antiparkinson Agents (pharmacology) »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Antiparkinson Agents (pharmacokinetics) < Antiparkinson Agents (pharmacology) < Antiparkinson Agents (therapeutic use)  Facettes :

List of bibliographic references indexed by Antiparkinson Agents (pharmacology)

Number of relevant bibliographic references: 45.
[0-20] [0 - 20][0 - 45][20-40]
Ident.Authors (with country if any)Title
000464 (2016) Lucia Ricciardi [Royaume-Uni] ; Francesco Bove [Italie] ; Kristy J. Espay [États-Unis] ; Francesco Lena [Italie] ; Nicola Modugno [Italie] ; Yu-Yan Poon [Canada] ; Robert Krikorian [États-Unis] ; Alberto J. Espay [États-Unis] ; Alfonso Fasano [Canada]24-Hour infusion of levodopa/carbidopa intestinal gel for nocturnal akinesia in advanced Parkinson's disease.
000488 (2015) Janelle Drouin-Ouellet ; Isabelle St-Amour ; Martine Saint-Pierre ; Jérôme Lamontagne-Proulx ; Jasna Kriz ; Roger A. Barker ; Francesca CicchettiToll-Like Receptor Expression in the Blood and Brain of Patients and a Mouse Model of Parkinson’s Disease
000731 (2015) Zaijun Zhang [République populaire de Chine] ; Guohui Li [République populaire de Chine] ; Samuel S W. Szeto [République populaire de Chine] ; Cheong Meng Chong [République populaire de Chine] ; Quan Quan [République populaire de Chine] ; Chen Huang [République populaire de Chine] ; Wei Cui [République populaire de Chine] ; Baojian Guo [République populaire de Chine] ; Yuqiang Wang [République populaire de Chine] ; Yifan Han [République populaire de Chine] ; K W Michael Siu [Canada] ; Simon Ming Yuen Lee [République populaire de Chine] ; Ivan K. Chu [République populaire de Chine]Examining the neuroprotective effects of protocatechuic acid and chrysin on in vitro and in vivo models of Parkinson disease.
000786 (2015) Nicolas Morin [Canada] ; Marc Morissette [Canada] ; Laurent Grégoire [Canada] ; Alex Rajput [Canada] ; Ali H. Rajput [Canada] ; Thérèse Di Paolo [Canada]Contribution of brain serotonin subtype 1B receptors in levodopa-induced motor complications.
000877 (2014) Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Katie D. Lewis [Australie] ; James B. Koprich [Canada] ; M Gabriela Reyes [Canada] ; Susan H. Fox [Canada] ; Matthew J. Piggott [Australie] ; Jonathan M. Brotchie [Canada]UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset.
000B38 (2014) Kristina Martinu [Canada] ; Atsuko Nagano-Saito [Canada] ; Stuart Fogel [Canada] ; Oury Monchi [Canada]Asymmetrical Effect of Levodopa on the Neural Activity of Motor Regions in PD
000C92 (2013) Vincent A. Jourdain [Canada] ; Laurent Grégoire ; Marc Morissette ; Nicolas Morin ; Martin Parent ; Thérèse Di PaoloPotentiation of response to low doses of levodopa in MPTP-injected monkeys by chemical unilateral subthalamotomy.
000D42 (2013) Nicolas Morin [Canada] ; Laurent Grégoire ; Marc Morissette ; Sandrine Desrayaud ; Baltazar Gomez-Mancilla ; Fabrizio Gasparini ; Thérèse Di PaoloMPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates.
000D57 (2013) David Mongeon [Canada] ; Pierre Blanchet ; Julie MessierImpact of Parkinson's disease and dopaminergic medication on adaptation to explicit and implicit visuomotor perturbations.
000E13 (2013) Madeleine E. Sharp [Canada] ; Jayalakshmi Viswanathan ; Martin J. Mckeown ; Silke Appel-Cresswell ; A Jon Stoessl ; Jason J S. BartonDecisions under risk in Parkinson's disease: preserved evaluation of probability and magnitude.
000E88 (2013) Lorraine V. Kalia [Canada] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada]Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials
001123 (2012) Laure Chagniel [Canada] ; Christine Robitaille ; Manon Lebel ; Michel CyrStriatal inhibition of calpains prevents levodopa-induced neurochemical changes and abnormal involuntary movements in the hemiparkinsonian rat model.
001191 (2012) Philippe Huot [Canada] ; Tom H. Johnston ; James B. Koprich ; Ahmed Aman ; Susan H. Fox ; Jonathan M. BrotchieL-745,870 reduces L-DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
001406 (2012) K. Martinu [Canada] ; C. Degroot [Canada] ; C. Madjar [Canada] ; A. P. Strafella [Canada] ; O. Monchi [Canada]Levodopa influences striatal activity but does not affect cortical hyper‐activity in Parkinson’s disease
001473 (2012) Alain Dagher [Canada]ADDICTION AS ABERRANT LEARNING—EVIDENCE FROM PARKINSON'S DISEASE
001601 (2011) James K R. Stevenson [Canada] ; Meeko M K. Oishi ; Sara Farajian ; Edmond Cretu ; Edna Ty ; Martin J. MckeownResponse to sensory uncertainty in Parkinson's disease: a marker of cerebellar dysfunction?
001681 (2011) Lori-Ann R. Sacrey [Canada] ; Scott G. Travis ; Ian Q. WhishawDrug treatment and familiar music aids an attention shift from vision to somatosensation in Parkinson's disease on the reach-to-eat task.
001714 (2011) E P Pasman [Canada] ; C D Murnaghan ; B R Bloem ; M G CarpenterBalance problems with Parkinson's disease: are they anxiety-dependent?
001723 (2011) Philippe Huot [Canada] ; Susan H. Fox ; Adrian Newman-Tancredi ; Jonathan M. BrotchieAnatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson's disease: an approach to reducing dyskinesia without exacerbating parkinsonism?
001A57 (2010) Bazoumana Ouattara [Canada] ; Fabrizio Gasparini ; Marc Morissette ; Laurent Grégoire ; Pershia Samadi ; Baltazar Gomez-Mancilla ; Thérèse Di PaoloEffect of L-Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys.
001C23 (2010) Bernard Ng [Canada] ; Samantha Palmer [Canada] ; Rafeef Abugharbieh [Canada] ; Martin J. Mckeown [Canada]Focusing effects of L‐dopa in Parkinson's disease

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i -k "Antiparkinson Agents (pharmacology)" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i  \
                -Sk "Antiparkinson Agents (pharmacology)" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    KwdEn.i
   |clé=    Antiparkinson Agents (pharmacology)
}}

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022